← Patent-cliff monitor small molecule ZEMDRI PLAZOMICIN SULFATE
Loss of exclusivity June 2032 latest FDA-listed patent expiry
Company Cipla → See this company's full patent-cliff portfolio Drug detail Brand name ZEMDRI Active ingredient PLAZOMICIN SULFATE Strength EQ 500MG BASE/10ML (EQ 50MG BASE/ML) Dosage form SOLUTION Route INTRAVENOUS Modality Small molecule FDA approval June 2018 Marketing status DISCN
Listed patents Patent Expires Type 8383596 June 2032 substance 9688711 November 2028 substance 9266919 November 2028 use U-2328 8822424 November 2028 product
Regulatory exclusivity Code Expires GAIN June 2028 NCE June 2023
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.